Article Text

Download PDFPDF
Review: verteporfin plus photodynamic therapy reduces loss of vision in age related macular degeneration

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 Q In patients with neovascular age related macular degeneration (AMD), what is the effect of photodynamic therapy?

Clinical impact ratings GP/FP/Primary care ★★★★☆☆☆


Embedded ImageData sources:

Cochrane Central Register of Controlled Trials, Medline, EMBASE/Excerpta Medica (to January 2003), Science Citation Index; reference lists; and contact with experts.

Embedded ImageStudy selection and assessment:

randomised controlled trials that compared photodynamic therapy with placebo, no treatment, or another treatment in people with neovascular AMD.

Embedded ImageOutcome:

prevention of visual loss.


2 studies (948 participants) were included. Both studies compared verteporfin, 6 mg/m2 (intravenous infusion of 30 ml/10 min), plus …

View Full Text


  • For correspondence: Mr R Wormald, Moorfields Eye Hospital and Institute of Ophthalmology, London, UK.

  • Source of funding: no external funding.